{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:37:20Z","timestamp":1777246640014,"version":"3.51.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fujian Provincial Science and Technology Project","award":["2024Y9056"],"award-info":[{"award-number":["2024Y9056"]}]},{"name":"Fujian Provincial Science and Technology Project","award":["2024Y9027"],"award-info":[{"award-number":["2024Y9027"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2017J01244"],"award-info":[{"award-number":["2017J01244"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J01084"],"award-info":[{"award-number":["2025J01084"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J011021"],"award-info":[{"award-number":["2022J011021"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J01510"],"award-info":[{"award-number":["2025J01510"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J01839"],"award-info":[{"award-number":["2023J01839"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and the rate of complete response in uHCC following triple therapy is relatively low. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 29 patients with uHCC who received sequential radiotherapy after achieving partial response (PR) or stable disease (SD) in tumor response per the modified Response Evaluation Criteria in Solid Tumors (mRECIST) after triple therapy. The overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were analyzed to evaluate the efficacy of this regimen. Treatment-related adverse events were assessed to determine the safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 29 patients, the median OS had not yet been reached, and the median PFS was 19.43\u2009months. The 24-month OS and PFS rates were 72.8% and 46.5%, respectively. The lesions of 6 patients initially with tumor response of PR achieved complete response, and the lesions of 12 patients with SD achieved PR after sequential radiotherapy. All adverse events were manageable, and no treatment-related death occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sequential radiotherapy after triple therapy enhanced tumor response and survival benefits for uHCC patients, with manageable adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag138","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T11:39:30Z","timestamp":1776598770000},"source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC"],"prefix":"10.1093","volume":"31","author":[{"given":"Xiangye","family":"Ou","sequence":"first","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhai","family":"Li","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]},{"name":"Department of Hepatobiliary Pancreatic Surgery, The Third Affiliated Hospital of Wenzhou Medical University , Wenzhou, Zhejiang, 325200,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongjian","family":"Pan","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Wu","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]},{"name":"Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital , Fuzhou, Fujian Province, 350001,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital , Fuzhou, Fujian Province, 350001,","place":["China"]},{"name":"The Affiliated People\u2019s Hospital of Fujian University of Traditional Chinese Medicine , Fuzhou, Fujian Province, 350000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinan","family":"Li","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenxin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyi","family":"Wu","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]},{"name":"Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital , Fuzhou, Fujian Province, 350001,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-2661","authenticated-orcid":false,"given":"Maolin","family":"Yan","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University , Fuzhou, Fujian Province, 350004,","place":["China"]},{"name":"Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital , Fuzhou, Fujian Province, 350001,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026042618470538700_oyag138-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026042618470538700_oyag138-B2","author":"National Comprehensive Cancer Network"},{"key":"2026042618470538700_oyag138-B3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026042618470538700_oyag138-B4","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026042618470538700_oyag138-B5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026042618470538700_oyag138-B6","first-page":"140","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"7","author":"Yau","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026042618470538700_oyag138-B7","doi-asserted-by":"crossref","first-page":"1110689","DOI":"10.3389\/fonc.2023.1110689","article-title":"Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"2026042618470538700_oyag138-B8","doi-asserted-by":"crossref","first-page":"709060","DOI":"10.3389\/fphar.2021.709060","article-title":"Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026042618470538700_oyag138-B9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12072-023-10502-3","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma","volume":"17","author":"Xin","year":"2023","journal-title":"Hepatol Int"},{"key":"2026042618470538700_oyag138-B10","doi-asserted-by":"crossref","first-page":"848387","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"2026042618470538700_oyag138-B11","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1245\/s10434-024-14944-3","article-title":"Outcomes of salvage surgery versus Non-Salvage surgery for initially unresectable hepatocellular carcinoma after conversion therapy with transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibody: a multicenter retrospective study","volume":"31","author":"Wu","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026042618470538700_oyag138-B12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000528356","article-title":"Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study","volume":"12","author":"Wu","year":"2023","journal-title":"Liver Cancer"},{"key":"2026042618470538700_oyag138-B13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000536376","article-title":"Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery","volume":"13","author":"Zeng","year":"2024","journal-title":"Liver Cancer"},{"key":"2026042618470538700_oyag138-B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.04.024","article-title":"Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion","volume":"134","author":"Mathew","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026042618470538700_oyag138-B15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijrobp.2019.05.066","article-title":"Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma","volume":"105","author":"Shen","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026042618470538700_oyag138-B16","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3389\/fonc.2019.01065","article-title":"Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion","volume":"9","author":"Zhao","year":"2019","journal-title":"Front Oncol"},{"key":"2026042618470538700_oyag138-B17","doi-asserted-by":"crossref","first-page":"972503","DOI":"10.3389\/fimmu.2022.972503","article-title":"PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: a propensity score matching study","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol"},{"key":"2026042618470538700_oyag138-B18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"2026042618470538700_oyag138-B19","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3748\/wjg.v29.i10.1614","article-title":"Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma","volume":"29","author":"Wang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026042618470538700_oyag138-B20","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s12325-023-02449-6","article-title":"Evaluating the benefits of TACE combined with lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus","volume":"40","author":"Zou","year":"2023","journal-title":"Adv Ther"},{"key":"2026042618470538700_oyag138-B21","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00432-021-03767-4","article-title":"Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study","volume":"148","author":"Chen","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026042618470538700_oyag138-B22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4143\/crt.2023.1165","article-title":"Efficacy of lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective, multicenter study","volume":"56","author":"Ou","year":"2024","journal-title":"Cancer Res Treat"},{"key":"2026042618470538700_oyag138-B23","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"key":"2026042618470538700_oyag138-B24","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026042618470538700_oyag138-B25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.32502","article-title":"A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy","volume":"126","author":"Jang","year":"2020","journal-title":"Cancer"},{"key":"2026042618470538700_oyag138-B26","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cncr.30008","article-title":"Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"key":"2026042618470538700_oyag138-B27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ijrobp.2017.02.095","article-title":"Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma","volume":"98","author":"Su","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026042618470538700_oyag138-B28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jhep.2020.03.005","article-title":"Stereotactic body radiation therapy vs. radiofrequency ablation in asian patients with hepatocellular carcinoma","volume":"73","author":"Kim","year":"2020","journal-title":"J Hepatol"},{"key":"2026042618470538700_oyag138-B29","doi-asserted-by":"crossref","first-page":"839605","DOI":"10.3389\/fonc.2022.839605","article-title":"Effects of stereotactic body radiation therapy plus PD-1 inhibitors for patients with transarterial chemoembolization refractory","volume":"12","author":"Xiang","year":"2022","journal-title":"Front Oncol"},{"key":"2026042618470538700_oyag138-B30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000513706","article-title":"Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein","volume":"10","author":"Kosaka","year":"2021","journal-title":"Liver Cancer"},{"key":"2026042618470538700_oyag138-B31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2147\/IJGM.S403316","article-title":"Evaluation of the clinical efficacy of intensity-modulated radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with extrahepatic oligometastasis and prognostic factors for patient survival","volume":"16","author":"Luo","year":"2023","journal-title":"Int J Gen Med"},{"key":"2026042618470538700_oyag138-B32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett"},{"key":"2026042618470538700_oyag138-B33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/imr.12568","article-title":"Immune recognition of irradiated cancer cells","volume":"280","author":"Wennerberg","year":"2017","journal-title":"Immunol Rev"},{"key":"2026042618470538700_oyag138-B34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/cancers13040678","article-title":"Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: a comprehensive review and latest developments","volume":"13","author":"Procureur","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026042618470538700_oyag138-B35","first-page":"65","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026042618470538700_oyag138-B36","doi-asserted-by":"crossref","first-page":"oyaf182","DOI":"10.1093\/oncolo\/oyaf182","article-title":"Regarding RECIST in retrospective studies","volume":"30","author":"Wu","year":"2025","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag138\/68131990\/oyag138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag138\/68131990\/oyag138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag138\/68131990\/oyag138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:20Z","timestamp":1777243640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag138\/8660470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag138","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,10]]},"article-number":"oyag138"}}